Hemocentro de São José do Rio Preto, Sáo Paulo, Brazil CYP17 gene encodes the enzyme cytochrome p450c17a, which mediates two steps in the steroid biosynthesis pathway. Steroid hormones are believed to play a key role in the etiology of prostate cancer. A polymorphic T?C transition in the 5 0 promoter region of CYP17 creates an additional Sp1-type (CCACC box) promoter site (allele A2). We have evaluated the genotypic and allelic distribution of this polymorphism among 92 prostate cancer patients in order to assess risk by comparison with a population-based series of 200 healthy individuals from Brazil. Our results provide no evidence for an association between prostate cancer risk and CYP17 T/C polymorphism. Prostate Cancer and Prostatic Diseases (2002) 5, 28-31. DOI: 10.1038/sj/pcan/4500550
Introduction
Prostate cancer is the most common malignancy and the third most common cause of cancer mortality in Brazilian men. 1 Studies of risk factors such as occupation, diet, smoking, alcohol and sexual activity are still inconclusive, however, age, ethnicity and family history clearly affect the risk of prostate cancer. 2 -7 There is evidence to support the hypothesis of hormonal etiology of prostate cancer involving androgen action. 8 -10 Androgen is required for differentiation and growth of the prostate in utero and at puberty. 8 Testosterone, the most abundant circulating androgen is synthesized from cholesterol by a series of enzymatic reactions involving the cytochrome p450c17a. The enzyme has a bifunctional active site: the catalytic center performs the 17a-hydroxylation of pregnenolone and progesterone while the 17,20-lyase activity is responsible for the conversions of 17a-hydroxypregnenolone to dehydroepiandrosterone and 17a-hydroxyprogesterone to androstenedione, precursors of testosterone and estrogen. 11 Testosterone is converted to 5a-dihydrotestosterone (DHT) in the prostate by the enzyme 5a-reductase. DHT binds to AR (androgen receptor gene), and the DHT -AR complex transactivates a number of genes with ARresponsive elements. These events ultimately result in cell division in the prostate. 12 The CYP17 gene codes for cytochrome p450c17a enzyme, is located on chromosome 10, spans 6569 bp, and is divided into eight exons. 13 A polymorphic T?C transition in the 5 0 promoter region of CYP17 creates an additional Sp1-type (CCACC box) promoter site. 14 This base pair change also creates a recognition site for the MspA I restriction enzyme, which allows the identification of the CYP17 A2 allele. Since the number of 5 0 promoter elements correlates with promoter activity, it has been proposed that the A2 allele may lead to an increased rate of transcription, thus increasing the prostate cancer risk. 15 Recent in vitro evidence suggests that the 5 0 Sp1 type site resulting from the T to C substitution does not actually bind transcription factor Sp1, but there is still some functional evidence to indicate that this polymorphism may act as a risk factor in hormonerelated cancers. 16 In the present study, we have determined the frequencies of the aforementioned polymorphism among 92 prostate cancer patients in order to assess risk by comparison with a population-based series of 200 healthy individuals from Sã o Paulo state, south-eastern Brazil. This is a highly mixed population, where significant contributions from European, African and Amerindian gene pools can be found. 17 Thus, it is important to define the polymorphic spectrum of genes that may be involved in cancer diseases in such a population, to evaluate its usefulness in the prediction of risk.
Materials and methods
The polymorphism of CYP17 gene was analyzed in DNA samples of 92 patients (mean ¼ 73.64 y and s.d. ¼ 9.17) with prostate adenocarcinoma examined by one of the authors (JCM) and of 200 male blood donors (mean ¼ 37.62 y and s.d. ¼ 9.59) from two HematologyHemotherapy Centers of the Sã o Paulo State. This group forms the base population for analysis, since there is no published information about the CYP17 polymorphism in a highly mixed Brazilian population. Information on ancestors of the study subjects was additionally obtained in order to characterize the ethnic background of both groups. Patients and blood donors were assigned as 'white' (Caucasian descent) and 'non-white' (African descent). Among the patients, 91% (n ¼ 84) were considered white and only 9% (n ¼ 8) had parents or grandparents of African ancestry. In the blood donor's sample, 64% (n ¼ 128) considered themselves white and 26% (n ¼ 72) reported African ancestry. No individuals reported Amerindian or Asian ancestry in the last two generations. All individuals were included in this study after having given informed written consent.
The CYP17 A1/A2 alleles were detected by restriction fragment length polymorphism (RFLP) analysis of 629 bp DNA fragments amplified by polymerase chain reaction (PCR, 35 cycles, annealing temperature of 58 C) with the primers described by Lunn et al. 18 The A2 allele can be identified by the presence of a second MspAI site created by the T?C substitution. The PCR fragments were digested with MspAI for 2 h at 37 C and the digestion products were separated on 3.0% Agarose 1000 (Gibco-BRL) gel electrophoresis. Specific digestion products consisted of 577; 577/305 and 272; 305/272 bp fragments for the A1/A1, A1/A2 and A2/A2 genotypes respectively. A 52 bp fragment was present in all samples due to an invariant MspA1 site that served as an internal control for complete digestion.
Statistical analysis
Chi-squared test with significance at the level of P < 0.05 was used to compare genotypes and alleles and for Hardy-Weinberg model fitting. The relative risk for each genotype was calculated with a 95% confidence interval.
Results
Preliminary comparative analysis showed no differences concerning ancestor's origin, in the base population sample (w 2 (2) ¼ 2.084, P ¼ 0.35). The frequencies of the A1/A1, A1/A2 and A2/A2 genotypes were similar in patients and combined base population (Table 1) . Genotypic and allelic distributions are in Hardy-Weinberg equilibrium and there were no statistically significant differences in the genotypic and allelic frequencies between these two groups (w 2 (2) ¼ 0.728, P ¼ 0.69 and w 2
(1) ¼ 0.47, P ¼ 0.49, respectively). In addition, there were no substantial differences in the estimated relative risk (RR) between the three CYP17 genotypes A1/A1, A1/A2 and A2/A2. Thus, our results indicate a lack of association of the CYP17 polymorphism and prostate cancer risk.
Discussion
We evaluated the genotypic and allelic distribution of the CYP17 5 0 UTR polymorphism in prostate cancer patients and healthy volunteers of a Brazilian population sample. There was no published data on the frequencies of this polymorphism in South America. We found that the frequencies of the A1/A1, A1/A2 and A2/A2 genotypes observed in the population-based series of the present study are very close to those observed by Lunn et al 18 in a mixed North American male population (Table 2 ) and do 19 When compared to other control series, significant differences are found in relation to one European sample 20 (w 2 (2) ¼ 7.284, P ¼ 0.02) and to Japanese populations 19, 21, 22 (w 2 (8) ¼ 33.374, P ¼ 0.0001). Thus, although the ethnic background seems to be clearly related to the allelic frequencies of the CYP17 polymorphism in some populations, its effect might be diluted in mixed populations. On the other hand, there seems to be no influence of age or sex on the CYP17 genotypic frequencies within populations with the same ethnic background, since no statistical differences were observed for the Japanese study groups (w 2 (6) ¼ 1.818, P ¼ 0.93), represented on Table 2 .
Our results indicate a lack of association of the CYP17 polymorphism and prostate cancer risk, since no differences in the genotypic or allelic frequencies were found between the patient's group and the base population sample. In prostate cancer research, there are contradictory data concerning the hypothesized CYP17 A2 risk allele. In a case -control study, Lunn et al 18 found that the A2 allele occurs more frequently in prostate cancer patients but demonstrated an increased risk only when A1/A2 and A2/A2 genotypes were combined. Gsur et al. 23 showed an association between the allele A2 and prostate cancer in men with A2/A2 genotype, but not in A1/A2 heterozygotes, when compared to individuals with benign prostatic hyperplasia (BPH). On the other hand, Wadelius et al 20 indicated an association between prostate cancer and the A1/A1 genotype, as compared to age matched controls, selected without screening for prostate cancer. Finally, Habuchi et al 22 observed that men with the CYP17 A1 allele had an increased risk both for prostate cancer and BPH. According to these authors, the A1/A1, A1/A2 and A2/A2 genotypes could confer, respectively, increased, intermediate and lower prostate cancer and BPH risks.
Similar controversies concerning the association of this polymorphism and breast cancer risk have been published. While some authors suggested that the CYP17 A2 allele was associated with an increased risk of the disease 24 others reported no difference in the distribution of the different alleles among healthy and breast cancer patients. 16, 25 The strong experimental evidence that the T to C substitution does not create a binding site for Sp-1 16 refutes the hypothesis that the CYP17 A2 would be the risk allele and suggest that these genotypes alone are of little value for breast cancer risk estimation. 25 
Conclusion
Our data provides no evidence for an association between prostate cancer risk and the genotypes defined by the T/ C polymorphism in the promoter region of the CYP17 gene. Alternative gene candidates are being investigated, and the possibility of gene -gene interactions between the CYP17 polymorphism and other candidate genes will be explored as the data become available. 
